Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.
Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F, Cantonetti M, Stelitano C, Feldman T, Gavarotti P, Sorasio R, Mulè A, Leone M, Rambaldi A, Biggi A, Barrington S, Fallanca F, Ficola U, Chauvie S, Gianni AM; Gruppo Italiano Terapie Innovative nei Linfomi (GITIL). Gallamini A, et al. Br J Haematol. 2011 Mar;152(5):551-60. doi: 10.1111/j.1365-2141.2010.08485.x. Epub 2010 Dec 20. Br J Haematol. 2011. PMID: 21166786 Free article. Clinical Trial.
International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.
Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, Meignan M, Malkowski B, Hofman MS, Barrington SF. Biggi A, et al. Among authors: gallamini a. J Nucl Med. 2013 May;54(5):683-90. doi: 10.2967/jnumed.112.110890. Epub 2013 Mar 20. J Nucl Med. 2013. PMID: 23516309 Free article.
Peripheral blood CD34+ percentage at hematological recovery after chemotherapy is a good early predictor of harvest: a single-center experience.
Sorasio R, Bonferroni M, Grasso M, Strola G, Rapezzi D, Marenchino D, Di Marco C, Castellino C, Mattei D, Mordini N, Fiore F, Celeghini I, Borra A, Ghiglia A, Gallamini A. Sorasio R, et al. Among authors: gallamini a. Biol Blood Marrow Transplant. 2014 May;20(5):717-23. doi: 10.1016/j.bbmt.2014.02.002. Epub 2014 Feb 11. Biol Blood Marrow Transplant. 2014. PMID: 24525280 Free article. Clinical Trial.
Role of PET in lymphoma.
Gallamini A, Borra A. Gallamini A, et al. Curr Treat Options Oncol. 2014 Jun;15(2):248-61. doi: 10.1007/s11864-014-0278-4. Curr Treat Options Oncol. 2014. PMID: 24619427 Review.
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.
Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, Meignan M, Mikhaeel GN, Loft A, Zaucha JM, Seymour JF, Hofman MS, Rigacci L, Pulsoni A, Coleman M, Dann EJ, Trentin L, Casasnovas O, Rusconi C, Brice P, Bolis S, Viviani S, Salvi F, Luminari S, Hutchings M. Gallamini A, et al. Haematologica. 2014 Jun;99(6):1107-13. doi: 10.3324/haematol.2013.103218. Epub 2014 Mar 21. Haematologica. 2014. PMID: 24658820 Free PMC article.
WIDEN: A tool for medical image management in multicenter clinical trials.
Chauvie S, Biggi A, Stancu A, Cerello P, Cavallo A, Fallanca F, Ficola U, Gregianin M, Guerra UP, Chiaravalloti A, Schillaci O, Gallamini A. Chauvie S, et al. Among authors: gallamini a. Clin Trials. 2014 Jun;11(3):355-361. doi: 10.1177/1740774514525690. Clin Trials. 2014. PMID: 24711610
Positron Emission Tomography (PET) in Oncology.
Gallamini A, Zwarthoed C, Borra A. Gallamini A, et al. Cancers (Basel). 2014 Sep 29;6(4):1821-89. doi: 10.3390/cancers6041821. Cancers (Basel). 2014. PMID: 25268160 Free PMC article. Review.
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).
Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, Bellò M, Rambaldi I, Gallamini A, Patriarca F, Gay F, Gamberi B, Cavo M, Fanti S. Nanni C, et al. Among authors: gallamini a. Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):414-21. doi: 10.1007/s00259-015-3200-9. Epub 2015 Oct 16. Eur J Nucl Med Mol Imaging. 2016. PMID: 26475305
The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma).
Chauvie S, Bergesio F, Fioroni F, Brambilla M, Biggi A, Versari A, Guerra L, Storto G, Musto P, Luminari S, Cabras MG, Balzarotti M, Rigacci L, Martelli M, Vitolo U, Federico M, Gallamini A. Chauvie S, et al. Among authors: gallamini a. Phys Med. 2016 May;32(5):651-6. doi: 10.1016/j.ejmp.2016.04.004. Epub 2016 Apr 28. Phys Med. 2016. PMID: 27133138
182 results